Abstract: The present invention relates to animal feed compositions comprising polypeptides having lysozyme activity and polypeptides having phytase activity and uses thereof.
Type:
Grant
Filed:
July 4, 2016
Date of Patent:
March 30, 2021
Inventors:
Dorthe Hoej Sandvang, Esben Gad, Nicholas Michael Kelly, Mikkel Klausen, Juliane Charlotte Gregaard Thoegersen, Peter Bjarke Olsen, Preben Nielsen, Marianne Thorup Cohn
Abstract: The present invention relates to modified producer cells for improved production of therapeutic proteins. Specifically, the inventors have found that removing genes involved in amino acid catabolism in Chinese Hamster Ovary (CHO) cells improves the cell growth and viability and likely also the yield of a recombinant therapeutic protein produced by the cells.
Type:
Grant
Filed:
August 15, 2017
Date of Patent:
March 30, 2021
Assignee:
DANMARKS TEKNISKE UNIVERSITET
Inventors:
Daniel Ley, Mikael Rørdam Andersen, Helene Faustrup Kildegaard
Abstract: This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.
Abstract: A process for treatment of hydrocarbon refinery wastewater producing a low bio-sludge, the process including utilizing microbial consortia comprising at least one species of Pseudomonas and at least one species of Bacillus in a ratio of 10:1 to 1:10. The species of Pseudomonas and species of Bacillus have constitutive expression of at least one hydrocarbon degrading gene. The species of Pseudomonas are selected from the group consisting of Pseudomonas stutzeri (MTCC 25027), Pseudomonas aeruginosa (MTCC 5389), Pseudomonas aeruginosa strain IOC DHT (MTCC, 5385), Pseudomonas putida IOCR1 (MTCC 5387), Pseudomonas putida IOC5a1 (MTCC 5388) and a mutant thereof. The species of Bacillus are selected from the group consisting of Bacillus subtilis (MTCC 25026), Bacillus substilis (MTCC 5386), Bacillus thermoleovorans (MTCC 25023), Bacillus stearothermophilus (MTCC 25030), Lysinibacillus sp. (MTCC 25029), Lysinibacillus sp. (MTCC 5666) and a mutant thereof.
Abstract: The present invention relates to terpene synthases capable of degrading precursors into biofuel compounds, such as terpenoid compounds. In one instance, a transformed organism can include such terpene synthases, as well as vectors encoding such synthases. Methods of employing such synthases and organisms are also described herein.
Type:
Grant
Filed:
July 15, 2019
Date of Patent:
March 16, 2021
Assignee:
National Technology & Engineering Solutions of Sandia, LLC
Inventors:
Weihua Wu, John Michael Gladden, Benjamin Chiau-Pin Wu, Ryan Wesley Davis
Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
Type:
Grant
Filed:
January 10, 2019
Date of Patent:
March 2, 2021
Assignee:
BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukherjee, Simeon I. Taylor
Abstract: The disclosure herein relates to construction and application of engineering bacteria capable of secreting and expressing diacetylchitobiose deacetylase, and belongs to the technical field of fermentation engineering. Firstly, recombinant B. subtilis capable of heterologously secreting and expressing a diacetylchitobiose deacetylase gene is constructed, and a signal peptide fragment yncM is added into the recombinant vector for the first time. The signal peptide can secrete the target protein diacetylchitobiose deacetylase outside the cells of the recombinant B. subtilis, and a mutant of the 5?-end untranslated region is acquired, thereby significantly increasing the expression level of the target protein, and greatly simplifying the subsequent enzyme separation and purification steps. When the acquired diacetylchitobiose deacetylase is fermented and cultured in a fermentation medium for 50-60 h, the enzyme activity reaches a maximum of 1,548.
Abstract: The present invention relates to methods for obtaining yeast strains suitable for metabolizing arabinose, and to improved strains with good performance as regards their capacity to ferment arabinose as well as xylose and glucose, including in the presence of inhibitors such as acetic acid.
Type:
Grant
Filed:
January 24, 2018
Date of Patent:
February 16, 2021
Assignee:
LESAFFRE et COMPAGNIE
Inventors:
Thomas Desfougeres, Emilie Fritsch, Georges Pignede, Christophe Rave, Claire Thorel
Abstract: Provided are improved methods for identifying the substrate recognition specificity or activity of a protease, convertase (sortase), or kinase. In some embodiments, methods are provided for identifying the endogenous protease or convertase cleaving patterns (e.g., “cleaveOme”) inside the secretory pathway of a living cell. Select embodiments involve aspects of yeast endoplasmic reticulum sequestration screening and next generation sequencing. Methods of producing polypeptides in Kex2 knockout yeast are also provided.
Type:
Grant
Filed:
October 14, 2015
Date of Patent:
January 26, 2021
Assignee:
Research Development Foundation
Inventors:
Brent Iverson, Peter Marek, Joseph Taft
Abstract: An object of the present invention is to provide a method for efficiently separating insoluble bodies of a recombinant protein from a recombinant cell expressing a target recombinant protein as insoluble bodies in the cell. The present invention provides a method for producing a recombinant protein aggregate by separating insoluble bodies of a recombinant protein from a recombinant cell expressing the recombinant protein as insoluble bodies in the cell, including disrupting the recombinant cell, aggregating the insoluble bodies of the recombinant protein, and separating the resulting aggregate.
Abstract: The present invention includes compositions and methods for preparing micron-sized or submicron-sized particles by dissolving a water soluble effective ingredient in one or more solvents; spraying or dripping droplets solvent such that the effective ingredient is exposed to a vapor-liquid interface of less than 50, 100, 150, 200, 250, 200, 400 or 500 cm?1 area/volume to, e.g., increase protein stability; and contacting the droplet with a freezing surface that has a temperature differential of at least 30° C. between the droplet and the surface, wherein the surface freezes the droplet into a thin film with a thickness of less than 500 micrometers and a surface area to volume between 25 to 500 cm?1.
Type:
Grant
Filed:
May 13, 2019
Date of Patent:
January 26, 2021
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Keith P. Johnston, Joshua Engstrom, Robert O. Williams, III
Abstract: A method for the production of pullulan soft capsules eliminates the need to dry pullulan solid product, thereby reducing the equipment cost and energy consumption. The pullulan raw material production can be linked directly with the soft capsule production to provide a unique approach for soft capsule formation. The purified pullulan fermentation fluid can be directly used in soft capsule preparation, thus removing the need for a melting process. On the one hand, the method can decrease material consumption, save the cost of equipment and labor, reduce production time and increase productivity. On the other hand, the method can reduce the fluctuating of raw material quality in the re-melting process and guarantee a more stable soft capsule production and quality.
Abstract: Disclosed in the present disclosure is a recombinant DNA polymerase. The recombinant DNA polymerase is any one selected from: A) a protein, having amino acid modifications at positions 408, 409 and 485, and at least one of amino acid modification(s) at positions 53, 59, 199, 243, 526, 558, 613, 641, 671, 673, 674, 692 and 709 compared to the amino acid sequence of a wild-type KOD DNA polymerase; B) a protein derived from the protein in A), formed by deleting amino acids 1 to 29 from a C-terminus of the protein in A) and keeping the remaining amino acids unchanged; and C) a protein derived from the protein in A) or B), formed by connecting a tag to the N-terminus or C-terminus of the amino acid sequence of the protein in A) or B), wherein the protein in A), B) and C) has DNA polymerase activity.
Abstract: The present invention relates to methods and products associated with in vivo enzyme profiling. In particular, the invention relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. The invention also relates to products, kits, and databases for use in the methods of the invention.
Type:
Grant
Filed:
April 30, 2018
Date of Patent:
January 5, 2021
Assignee:
Massachusetts Institute of Technology
Inventors:
Sangeeta N. Bhatia, Geoffrey A. von Maltzahn, Gabriel A. Kwong
Abstract: Oxygenases and methods of biologically upgrading hydrocarbon streams, such as crude oil, using oxygenases are provided herein. The oxygenases can be used to remove impurities such as metals, heteroatoms, or asphaltenes from a hydrocarbon stream. In some cases, the oxygenases can be chemically or genetically modified and can be used in different locations such as petroleum wells, pipes, reservoirs, tanks and/or reactors.
Type:
Grant
Filed:
November 12, 2018
Date of Patent:
January 5, 2021
Assignee:
ExxonMobil Research and Engineering Company
Inventors:
Zarath M. Summers, David O. Marler, Jay B. Patel, Katherine G. Landuyt
Abstract: Provided is a method for producing PHA by a microbe with improved productivity of PHA, and a PHA-producing microbe used for the production method. A method for producing polyhydroxyalkanoic acid, the method including a step of culturing a microbe having a polyhydroxyalkanoic acid synthase gene and an inactivated gene encoding a flagellar protein to cause the microbe to produce polyhydroxyalkanoic acid. In the microbe, a lipase, a dephosphorylating enzyme, and a protein represented by the amino acid sequence of SEQ ID NO: 6 or 7 may be additionally inactivated. The microbe may be Cupriavidus necator.
Abstract: A method for producing an objective substance such as vanillin and vanillic acid is provided. An objective substance is produced from a carbon source or a precursor of the objective substance by using a microorganism having an objective substance-producing ability, which microorganism has been modified so as to have a specific feature, such as a reduced activity of AICAR formyltransferase/IMP cyclohydrolase, an increased activity of 3-PGDH, and/or a reduced activity of L-serine deaminase.
Type:
Grant
Filed:
May 17, 2018
Date of Patent:
December 8, 2020
Assignee:
AJINOMOTO CO., INC.
Inventors:
Christine Roche, Benjamin Mijts, Peter Kelly, Matthew Davis, Sayaka Asari, Keita Fukui, Miku Toyazaki
Abstract: A method for forming microspheres containing bioactive material, comprising dissolving a polymer matrix, such as albumin or beta-cyclodextrin, in an aqueous medium in a first vessel; contacting the dissolved polymer matrix with a crosslinking agent, such as glutaraldehyde, to crosslink the polymer matrix and the crosslinking agent; neutralizing with sodium bisulfate any excess crosslinking agent remaining after crosslinking is substantially complete; solubilizing in a second vessel a bioactive material in an aqueous solution; mixing the solubilized bioactive material together with the neutralized crosslinked polymer matrix in solution to form a mixture; and, spray drying the mixture to produce nanospheres, whereby substantial bioactivity of the biomaterial is retained upon cellular uptake.
Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.
Type:
Grant
Filed:
November 27, 2018
Date of Patent:
November 24, 2020
Assignees:
Elastogenesis, LLC, The Hospital for Sick Children
Inventors:
Felipe Jimenez, Thomas Mitts, Aleksander Hinek